|
MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK
|
27 June 2023 at 4:10pm
|
|
First Patient Dosed in ATL1102 Phase IIb DMD Trial
|
8 June 2023 at 9:05am
|
|
Shareholder Newsletter
|
6 June 2023 at 4:10pm
|
|
Final Director's Interest Notice
|
12 May 2023 at 4:50pm
|
|
Change of Director's Interest Notice (JG)
|
11 May 2023 at 10:10am
|
|
Initial Director's Interest Notice
|
9 May 2023 at 9:45am
|
|
Chief Executive Officer and Managing Director Appointment
|
8 May 2023 at 9:05am
|
|
PIIb DMD trial approved in Bulgaria- UK, Australia advancing
|
26 April 2023 at 10:15am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
17 April 2023 at 10:00am
|
|
Dosing commenced in the ATL1102 toxicology study
|
14 March 2023 at 9:30am
|
|
Notice under Section 708A
|
7 March 2023 at 4:45pm
|
|
Application for quotation of securities - ANP
|
7 March 2023 at 4:40pm
|
|
Proposed issue of securities - ANP
|
6 March 2023 at 4:59pm
|
|
Receipt of R&D Tax Incentive Payment
|
23 February 2023 at 9:35am
|
|
Half Yearly Report and Accounts
|
22 February 2023 at 4:50pm
|
|
Presentation at International Conference on DMD
|
17 February 2023 at 10:10am
|
|
First approval for ATL1102 Phase IIb DMD clinical trial
|
14 February 2023 at 9:10am
|
|
Limb Girdle Muscular Dystrophy R2 animal study commenced
|
13 February 2023 at 10:10am
|
|
Positive outcomes in DMD combination therapy animal study
|
1 February 2023 at 10:20am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
25 January 2023 at 10:10am
|
|
Notification regarding unquoted securities - ANP
|
21 December 2022 at 5:30pm
|
|
Phase IIb DMD CTA submitted for trial conduct in Europe
|
19 December 2022 at 10:00am
|
|
Application for quotation of securities - ANP
|
23 November 2022 at 6:15pm
|
|
Final Director's Interest Notice (GWP)
|
22 November 2022 at 9:50am
|
|
Results of Annual General Meeting
|
17 November 2022 at 4:35pm
|
|
AGM Presentation
|
17 November 2022 at 2:15pm
|
|
Antisense Therapeutics CEO announces retirement
|
15 November 2022 at 9:45am
|
|
ATL1102 tox study to support clinical program in the US
|
14 November 2022 at 9:50am
|
|
Change of Registry Address
|
31 October 2022 at 4:25pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
26 October 2022 at 2:30pm
|
|
Appendix 4G
|
19 October 2022 at 9:35am
|
|
Corporate Governance Statement
|
19 October 2022 at 9:35am
|
|
Annual Report
|
19 October 2022 at 9:35am
|
|
Notice of Annual General Meeting
|
19 October 2022 at 9:30am
|
|
Non-Executive Director Retirement
|
14 October 2022 at 4:45pm
|
|
Receipt of further R&D Tax Incentive Payment
|
14 October 2022 at 8:45am
|
|
Change of Director's Interest Notice (GP)
|
7 October 2022 at 4:30pm
|
|
Company Appointment Chief Commercial Officer
|
5 October 2022 at 9:55am
|
|
Change of Director's Interest Notice (GP)
|
4 October 2022 at 9:30am
|
|
Change of Director's Interest Notice (GP)
|
29 September 2022 at 9:15am
|
|
Dosing commenced in DMD combination therapy study
|
12 September 2022 at 9:40am
|
|
ATL1102 Revised Clinical Development Plans Presentation
|
7 September 2022 at 9:30am
|
|
ATL1102 Revised Plans accelerate reporting of unblinded data
|
7 September 2022 at 9:25am
|
|
Appendix 4E and Full Year Statutory Accounts
|
31 August 2022 at 4:35pm
|
|
Ceasing to be a substantial holder
|
22 August 2022 at 4:25pm
|
|
Reinstatement to Official Quotation
|
19 August 2022 at 10:30am
|
|
Response to ASX Query
|
19 August 2022 at 10:30am
|
|
Long Covid-19 Collaboration Outcomes Presentation
|
19 August 2022 at 10:30am
|
|
Long COVID study identifies diagnostic & therapeutic targets
|
19 August 2022 at 10:30am
|
|
Voluntary Suspension
|
17 August 2022 at 12:35pm
|
Antisense Therapeutics